KR102035362B1 - (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제 - Google Patents

(+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제 Download PDF

Info

Publication number
KR102035362B1
KR102035362B1 KR1020147020953A KR20147020953A KR102035362B1 KR 102035362 B1 KR102035362 B1 KR 102035362B1 KR 1020147020953 A KR1020147020953 A KR 1020147020953A KR 20147020953 A KR20147020953 A KR 20147020953A KR 102035362 B1 KR102035362 B1 KR 102035362B1
Authority
KR
South Korea
Prior art keywords
weight
amount
coating formulation
delete delete
total coating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147020953A
Other languages
English (en)
Korean (ko)
Other versions
KR20140108707A (ko
Inventor
스리니바스 에스. 바트
마이클 티. 켈리
Original Assignee
셀진 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102035362(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 셀진 코포레이션 filed Critical 셀진 코포레이션
Publication of KR20140108707A publication Critical patent/KR20140108707A/ko
Application granted granted Critical
Publication of KR102035362B1 publication Critical patent/KR102035362B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
KR1020147020953A 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제 Active KR102035362B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161580626P 2011-12-27 2011-12-27
US61/580,626 2011-12-27
PCT/US2012/071623 WO2013101810A1 (en) 2011-12-27 2012-12-26 Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030218A Division KR102232154B1 (ko) 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제

Publications (2)

Publication Number Publication Date
KR20140108707A KR20140108707A (ko) 2014-09-12
KR102035362B1 true KR102035362B1 (ko) 2019-10-22

Family

ID=47459206

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020217008170A Ceased KR20210033073A (ko) 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
KR1020147020953A Active KR102035362B1 (ko) 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
KR1020197030218A Active KR102232154B1 (ko) 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020217008170A Ceased KR20210033073A (ko) 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197030218A Active KR102232154B1 (ko) 2011-12-27 2012-12-26 (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제

Country Status (34)

Country Link
US (2) US20130164376A1 (enExample)
EP (3) EP4623993A3 (enExample)
JP (1) JP6161629B2 (enExample)
KR (3) KR20210033073A (enExample)
CN (1) CN104136003A (enExample)
AU (1) AU2012362562B2 (enExample)
BR (1) BR112014015923B1 (enExample)
CA (1) CA2861594A1 (enExample)
CL (1) CL2014001726A1 (enExample)
CO (1) CO7000777A2 (enExample)
CR (1) CR20140314A (enExample)
CY (1) CY1123174T1 (enExample)
DK (2) DK2797581T3 (enExample)
EA (1) EA027801B1 (enExample)
EC (1) ECSP14007965A (enExample)
ES (2) ES3049175T3 (enExample)
FI (1) FI3756650T3 (enExample)
HR (2) HRP20251291T1 (enExample)
HU (1) HUE050327T2 (enExample)
IL (1) IL233296B (enExample)
LT (2) LT3756650T (enExample)
MX (2) MX373934B (enExample)
NI (1) NI201400068A (enExample)
PE (1) PE20142318A1 (enExample)
PH (1) PH12014501495B1 (enExample)
PL (1) PL2797581T3 (enExample)
PT (2) PT2797581T (enExample)
RS (2) RS60415B1 (enExample)
SG (2) SG10201605251VA (enExample)
SI (1) SI2797581T1 (enExample)
SM (2) SMT202500402T1 (enExample)
UA (1) UA113750C2 (enExample)
WO (1) WO2013101810A1 (enExample)
ZA (1) ZA201404629B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220047105A (ko) 2020-10-08 2022-04-15 주식회사 엔비피헬스케어 아프레밀라스트를 함유하는 약학 조성물

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12014500593A1 (en) 2011-09-14 2019-09-02 Celgene Corp Formulations of cyclopropanecarboxylic acid {2-(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2,3-dihydro-1h-isoindol-4-yl}-amidecelgene corporation state of incorporation:delaware
DK2797581T3 (da) 2011-12-27 2020-07-20 Amgen Europe Gmbh Formuleringer af (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methansulfonylethyl]-4-acetylaminoisoindolin-1,3-dion
EP3143004B1 (en) 2014-05-11 2020-09-02 Mapi Pharma Limited Amorphous form of apremilast
WO2016016824A1 (en) 2014-07-29 2016-02-04 Fundacio Hospital Universitari Vall D' Hebron-Institut De Recerca Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis
ES2969014T3 (es) * 2015-06-30 2024-05-16 Genentech Inc Comprimidos de liberación inmediata que contienen un fármaco y procesos para la formación de los comprimidos
CZ20165A3 (cs) * 2016-01-06 2017-07-19 Zentiva, K.S. Způsoby přípravy amorfního apremilastu
US20190175491A1 (en) 2016-06-15 2019-06-13 Torrent Pharmaceuticals Limited Topical compositions of apremilast
IL287665A (en) * 2019-04-30 2022-07-01 Celgene Corp Combined treatments including apremilaste and tyk2 inhibitors
ES2823927B2 (es) * 2019-11-07 2022-01-18 Beijing Enbiwo Biological Tech Co Ltd Composición en tamaño micrométrico y su uso como agente coadyuvante de alcaloides vegetales
CN112245403B (zh) * 2020-10-23 2022-04-22 杭州朱养心药业有限公司 磷酸二酯酶-4抑制剂及其口服固体组合物
EP4183389A1 (en) 2021-11-18 2023-05-24 KRKA, d.d., Novo mesto Pharmaceutical composition comprising apremilast
WO2023118043A1 (en) 2021-12-22 2023-06-29 Biohorm, S.L. Pharmaceutical compositions of apremilast

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
IT1274549B (it) 1995-05-23 1997-07-17 Indena Spa Uso di flavanolignani per la preparazione di medicamenti ad attivita' antiproliferativa nei tumori dell'utero,dell'ovaio e del seno
US5800819A (en) 1996-01-25 1998-09-01 National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease
CZ302378B6 (cs) 1996-07-24 2011-04-20 Celgene Corporation Optický izomer (S)-1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindolin a farmaceutická kompozice s jeho obsahem
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6015803A (en) 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6225348B1 (en) 1998-08-20 2001-05-01 Alfred W. Paulsen Method of treating macular degeneration with a prostaglandin derivative
US6001368A (en) 1998-09-03 1999-12-14 Protein Technologies International, Inc. Method for inhibiting or reducing the risk of macular degeneration
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6448323B1 (en) * 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
NZ518002A (en) * 1999-10-29 2004-01-30 Smithkline Beecham Corp Method for administering a phosphodiesterase 4 inhibitor
US7182953B2 (en) 1999-12-15 2007-02-27 Celgene Corporation Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
CN1511420A (zh) 2001-11-09 2004-07-07 ���µ�����ҵ��ʽ���� 运动图像编码方法和装置
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
US20050203142A1 (en) 2002-10-24 2005-09-15 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
US20040091455A1 (en) 2002-10-31 2004-05-13 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
US7563810B2 (en) 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
US20050100529A1 (en) 2003-11-06 2005-05-12 Zeldis Jerome B. Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
CN1913896B (zh) 2003-12-02 2010-12-01 细胞基因公司 用于治疗和控制血红蛋白病和贫血病的方法和组合物
US20050143344A1 (en) 2003-12-30 2005-06-30 Zeldis Jerome B. Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases
CN1956718A (zh) 2004-03-22 2007-05-02 细胞基因公司 用于治疗和控制皮肤疾病和病症的含免疫调节化合物的组合物和使用方法
US20050222209A1 (en) 2004-04-01 2005-10-06 Zeldis Jerome B Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease
KR20070010184A (ko) 2004-04-23 2007-01-22 셀진 코포레이션 폐 고혈압증의 치료 및 관리를 위한 면역조절 화합물의사용 방법 및 상기 화합물을 포함하는 조성물
CN101098694A (zh) 2004-11-12 2008-01-02 细胞基因公司 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物
ZA200704890B (en) 2004-11-23 2008-09-25 Celgene Corp Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury
WO2006060507A2 (en) 2004-12-01 2006-06-08 Celgene Corporation Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders
JP2008530145A (ja) * 2005-02-15 2008-08-07 ワイス 経口投与可能なｃｃｉ−７７９製剤
CA2600542A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Pharmaceutical tablets of crystalline type ii aripiprazole
WO2006111980A2 (en) 2005-04-20 2006-10-26 Ideal Cures Pvt. Ltd. Pva based film coating and film coating compositions
ATE499112T1 (de) 2005-09-01 2011-03-15 Celgene Corp Immunologische verwendungen von immunmodulatorischen verbindungen für einen impfstoff und therapie gegen infektionskrankheiten
US20070155791A1 (en) * 2005-12-29 2007-07-05 Zeldis Jerome B Methods for treating cutaneous lupus using aminoisoindoline compounds
US8927546B2 (en) * 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
MX359839B (es) * 2008-03-27 2018-10-12 Celgene Corp Formas solidas que comprenden (+)-2-[1-(3-etoxi-4-metoxifenil)-2-m etilsulfoniletil]-4-acetilaminoisoindolina-3, 3-diona, composiciones de la misma y usos de las mismas.
DE102008047910A1 (de) * 2008-09-19 2010-03-25 Molkerei Meggle Wasserburg Gmbh & Co. Kg Tablettierhilfsstoff auf Laktose- und Cellulosebasis
EP2196465A1 (en) * 2008-12-15 2010-06-16 Almirall, S.A. (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors
US20120149716A1 (en) 2009-02-10 2012-06-14 Zeldis Jerome B Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
SMT201800564T1 (it) * 2009-11-13 2018-11-09 Astrazeneca Ab Formulazioni in compressa a rilascio immediato
CA2821805A1 (en) * 2010-12-16 2012-06-21 Celgene Corporation Controlled release oral dosage forms of poorly soluble drugs and uses thereof
DK2797581T3 (da) 2011-12-27 2020-07-20 Amgen Europe Gmbh Formuleringer af (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methansulfonylethyl]-4-acetylaminoisoindolin-1,3-dion

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220047105A (ko) 2020-10-08 2022-04-15 주식회사 엔비피헬스케어 아프레밀라스트를 함유하는 약학 조성물

Also Published As

Publication number Publication date
CN104136003A (zh) 2014-11-05
SG10201605251VA (en) 2016-08-30
MX2020005145A (es) 2020-08-17
AU2012362562A1 (en) 2014-07-17
LT3756650T (lt) 2025-11-10
CR20140314A (es) 2014-10-28
EP3756650A1 (en) 2020-12-30
HRP20251291T1 (hr) 2025-12-05
CY1123174T1 (el) 2021-10-29
HRP20200825T1 (hr) 2020-08-07
DK2797581T3 (da) 2020-07-20
FI3756650T3 (fi) 2025-10-30
NI201400068A (es) 2016-01-28
WO2013101810A1 (en) 2013-07-04
US20130164376A1 (en) 2013-06-27
KR20140108707A (ko) 2014-09-12
MX373934B (es) 2020-07-10
CO7000777A2 (es) 2014-07-21
PH12014501495A1 (en) 2014-09-22
PH12014501495B1 (en) 2014-09-22
UA113750C2 (xx) 2017-03-10
HUE050327T2 (hu) 2020-11-30
ES3049175T3 (en) 2025-12-15
DK3756650T3 (da) 2025-11-03
CA2861594A1 (en) 2013-07-04
SMT202000339T1 (it) 2020-07-08
LT2797581T (lt) 2020-07-10
ECSP14007965A (es) 2015-11-30
EP2797581B1 (en) 2020-05-06
HK1202056A1 (en) 2015-09-18
US20210093573A1 (en) 2021-04-01
RS67339B1 (sr) 2025-11-28
EP2797581A1 (en) 2014-11-05
KR20210033073A (ko) 2021-03-25
EP3756650B1 (en) 2025-08-20
BR112014015923B1 (pt) 2022-02-01
PT2797581T (pt) 2020-06-18
AU2012362562B2 (en) 2017-11-02
MX2014007878A (es) 2015-03-23
JP2015506356A (ja) 2015-03-02
PT3756650T (pt) 2025-10-28
EA027801B1 (ru) 2017-09-29
BR112014015923A8 (pt) 2017-07-04
EA201491292A1 (ru) 2014-11-28
SMT202500402T1 (it) 2025-11-10
PL2797581T3 (pl) 2020-10-05
BR112014015923A2 (pt) 2017-06-13
EP4623993A3 (en) 2025-12-17
SG11201403564YA (en) 2014-07-30
ZA201404629B (en) 2017-08-30
CL2014001726A1 (es) 2014-11-14
JP6161629B2 (ja) 2017-07-12
EP4623993A2 (en) 2025-10-01
SI2797581T1 (sl) 2020-08-31
NZ626615A (en) 2016-08-26
ES2799448T3 (es) 2020-12-17
IL233296B (en) 2018-11-29
IL233296A0 (en) 2014-08-31
RS60415B1 (sr) 2020-07-31
KR102232154B1 (ko) 2021-03-25
KR20190120418A (ko) 2019-10-23
PE20142318A1 (es) 2015-01-16

Similar Documents

Publication Publication Date Title
KR102035362B1 (ko) (+)-2-[1-(3-에톡시-4-메톡시-페닐)-2-메탄술포닐-에틸]-4-아세틸아미노이소인돌린-1,3-디온의 제제
KR101381060B1 (ko) 4-아미노-2-(2,6-디옥소피페리딘-3-일)이소인돌린-1,3-디온의 제제
JP6339251B2 (ja) シクロプロパンカルボン酸｛２−［（１ｓ）−１−（３−エトキシ−４−メトキシ−フェニル）−２−メタンスルホニル−エチル］−３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−イル｝−アミドの製剤
HK40042486A (en) Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
HK1200356B (en) Formulations of cyclopropanecarboxylic acid {2-[(1s)-1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-3-oxo-2, 3-dihydro-1h-isoindol-4-yl}-amide
NZ626615B2 (en) Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione
HK1202056B (en) Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J206 Request for trial to confirm the scope of a patent right
PJ0206 Trial to confirm the scope of a patent

St.27 status event code: A-5-5-V10-V11-apl-PJ0206

J301 Trial decision

Free format text: TRIAL NUMBER: 2020100002991; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200929

Effective date: 20210524

Free format text: TRIAL NUMBER: 2020100002993; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200929

Effective date: 20210524

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20210524

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 2035362

Appeal request date: 20200929

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2020100002991

Decision date: 20210524

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 2035362

Appeal request date: 20200929

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2020100002993

J301 Trial decision

Free format text: TRIAL NUMBER: 2020100003002; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20201005

Effective date: 20210610

Free format text: TRIAL NUMBER: 2020100003054; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20201008

Effective date: 20210610

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20210610

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 2035362

Appeal request date: 20201008

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2020100003054

Decision date: 20210610

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 2035362

Appeal request date: 20201005

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2020100003002

J301 Trial decision

Free format text: TRIAL NUMBER: 2020100003072; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20201013

Effective date: 20210715

Free format text: TRIAL NUMBER: 2020100003076; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20201013

Effective date: 20210715

Free format text: TRIAL NUMBER: 2020100003080; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20201013

Effective date: 20210715

PJ1301 Trial decision

St.27 status event code: A-5-5-V10-V15-crt-PJ1301

Decision date: 20210715

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 2035362

Appeal request date: 20201013

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2020100003082

Decision date: 20210715

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 2035362

Appeal request date: 20201013

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2020100003080

Decision date: 20210715

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 2035362

Appeal request date: 20201013

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2020100003076

Decision date: 20210715

Appeal event data comment text: Appeal Kind Category : Confirmation of the scope of right_defensive, Appeal Ground Text : 2035362

Appeal request date: 20201013

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2020100003072

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6